Cy­to­ki­net­ics’ ALS drug fails PhI­II, leav­ing the biotech with a sin­gle late-stage prospect

Cy­to­ki­net­ics’ can­di­date for the mus­cle dis­ease amy­otroph­ic lat­er­al scle­ro­sis, or ALS, failed a Phase III tri­al, the Bay Area biotech an­nounced Fri­day morn­ing.

At a sec­ond in­ter­im analy­sis of the tri­al, an in­de­pen­dent re­view com­mit­tee rec­om­mend­ed that Cy­to­ki­net­ics dis­con­tin­ue its COURAGE-ALS tri­al for relde­sem­tiv, as it “found no ev­i­dence of ef­fect” com­pared to place­bo on the pri­ma­ry or key sec­ondary end­points.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN